Variational AI
- Company typePrivate
- Founded2019
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Variational AI firmographics
Firmographics- Name
- Variational AI
- Legal name
- Variational AI Inc.
- Website
- http://variational.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Variational AI is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Variational AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Strategic Partnership Payments: Receives upfront payments plus potential milestone payments structured as 'biobucks' from pharmaceutical partnerships. Merck partnership includes undisclosed upfront payment plus milestone payments. No royalties on eventual sales. Partnership value up to $349M USD.
- Collaborative Research Funding: B2B collaborations with biotech and pharma companies for specific drug discovery programs. Includes expanded AI collaborations with companies like Rakovina Therapeutics for ATR inhibitors and other therapeutic targets.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Variational AI product offering
Product offeringCore offering
Variational AI develops and licenses Enki™, a generative AI foundation model that designs novel, synthesis-ready small-molecule drug candidates de novo. The platform is offered to pharmaceutical and biotechnology partners through direct strategic collaboration agreements, with Enki powering partner lead-generation and lead-optimization workflows spanning kinases, GPCRs, and proximity-based therapeutic modalities.
Product overview
Variational AI offers a single unified platform, Enki™, a generative AI system built on variational autoencoders for small-molecule drug discovery. Enki™ enables direct generation of synthesis-ready lead candidates by jointly optimizing potency, selectivity, ADMET, and synthetic feasibility—eliminating traditional screening libraries and hit-to-lead phases. The platform is offered as a web application (Enki App) accessible to pharma and biotech partners for lead generation and iterative optimization workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Enki™: Generative AI platform for early-stage drug discovery that generates optimized, synthesis-ready, lead-like compounds tailored to target product profiles. Supports 760 drug targets including kinases, GPCRs, proteases, and other target classes.
Products and services
- Enki™ Generative AI Drug Discovery Platform Generative AI platform for early-stage small-molecule drug discovery. Generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile across kinases, GPCRs, proteases and other target classes, allowing pharma and biotech partners to bypass hit ID and hit-to-lead and move directly into Lead Optimization. Delivered as the Enki web application accessed by partners.
- Enki™ 4 Updated release of the Enki platform with broader pre-trained target coverage and support for proximity-based therapeutic modalities. Targeted at the same pharma/biotech partner base to enable generative AI design of degraders, PROTACs and ADC linkers in addition to small molecules.
Quantifiable outcome
- 100 AI-generated molecules outperform 1,000,000 molecule high-throughput screening library in benchmark tests
- +3 more outcomes
Companies that use Variational AI
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles3 records
Variational AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Variational AI partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor/exploratory, core/flagship and core.
- 3C Therapeuticsminor/exploratoryCollaboration to apply Variational AI's Enki platform to ligand design for 3C Therapeutics' proprietary TriCore DAC platform for degrader antibody conjugates. Supported by Innovate BC's Integrated Marketplace program.
- Agora Open Science Trustminor/exploratoryOpen-science collaboration to discover novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA). Project utilizes AI-driven design, synthetic chemistry, and open science principles to accelerate drug discovery with international partners emphasizing transparency and rapid iteration.
- Rakovina Therapeuticscore/flagshipExpanded collaboration to advance kt-5000 series ATR inhibitors for cancer treatment. Enki applied in iterative optimization loop generating and prioritizing optimized compound designs to progress from early leads toward clinical candidates faster (months vs years). Rakovina retains full control over which candidates advance and owns all compounds developed.
- Merckcore/flagshipTwo-year development deal potentially worth up to US$349-million. Variational AI uses Enki platform to generate promising molecules for challenging therapeutic targets selected by Merck. Merck receives exclusive rights to develop and commercialize resulting compounds. Variational receives undisclosed upfront payment plus milestone payments ('biobucks') but no royalties on eventual sales. Merck previously invested US$5.5M in Variational's seed extension round.
- Life ChemicalscoreSecond collaboration following successful 2022 SARS-CoV-2 main protease project. Focus on discovering de novo generated selective dual EGFR/FGFR1 inhibitors using Enki platform. Generated 40 molecules fitting target product profile; 19 synthesized with 5 showing dual EGFR+FGFR1 activity. Lead compound: EGFR IC50 = 29nM, FGFR1 IC50 = 175nM.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Variational AI competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: End-to-end generative AI drug discovery platform with Pharma.AI suite covering target identification, molecule generation, and clinical development. Competes directly with Enki for enterprise pharma partnerships in small-molecule discovery.
- Schrödinger: Computational chemistry platform combining physics-based simulation with machine learning for small-molecule drug discovery. Directly comparable in target customers (large pharma) and core offering (in silico lead generation and optimization).
- Iambic Therapeutics: Generative AI platform for small-molecule drug discovery using neural network-based molecule design and multi-parameter optimization. Closest direct competitor in technology approach and pharma partnership model.
- Atomwise: AI-driven small-molecule discovery company using convolutional neural networks for structure-based drug design. Targets similar pharma and biotech customer base with comparable lead-generation partnerships.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning across small molecules and biologics. Broader scope than Variational AI but directly comparable in offering AI-driven discovery partnerships to pharma.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to molecular design and protein structure prediction. Direct competitor for large-pharma generative chemistry partnerships.
- XtalPi: AI-driven drug discovery platform combining quantum physics, AI, and high-performance computing for small-molecule design. Comparable in offering AI lead-generation partnerships to global pharma.
Emerging players
- Aqemia: Generative AI drug discovery platform combining proprietary physics-inspired algorithms with deep learning for small-molecule lead generation. Similar stage and partnership-led GTM motion with pharma.
- Cradle Bio: Generative AI platform for protein and biologics design, adjacent to Variational AI's small-molecule focus but serving overlapping pharma R&D buyers with comparable enterprise partnership model.
- Generate Biomedicines: Generative biology company using AI to design novel protein therapeutics. Adjacent in generative-AI-for-drug-discovery category with comparable enterprise partnership GTM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Variational AI social profiles
Digital presenceVariational AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Variational AI leadership team
Management profileNumber of profiles
Profiles8 records
Variational AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Variational AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Variational AI
What does Variational AI do?
Variational AI develops and licenses Enki™, a generative AI foundation model that designs novel, synthesis-ready small-molecule drug candidates de novo. The platform is offered to pharmaceutical and biotechnology partners through direct strategic collaboration agreements, with Enki powering partner lead-generation and lead-optimization workflows spanning kinases, GPCRs, and proximity-based therapeutic modalities.
Is Variational AI a public or private company?
Variational AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Variational AI founded?
Variational AI was founded in 2019. It employs 11 to 50 people.
Where is Variational AI based?
Variational AI is headquartered in Vancouver, Canada, in the North America region.
How does Variational AI make money?
Two revenue lines are on record. Strategic Partnership Payments are the primary driver. The others are collaborative Research Funding.
Who are Variational AI's main competitors?
Direct peers on record are Insilico Medicine, Schrödinger, Iambic Therapeutics, Atomwise, Recursion Pharmaceuticals, Isomorphic Labs and XtalPi. Emerging players are Aqemia, Cradle Bio and Generate Biomedicines.
Does Variational AI have an API?
No public API is recorded for Variational AI.